Oncology

  • 18 February 2019
    News

    Lilly closes $8bn Loxo Oncology acquisition

    Eli Lilly has completed the acquisition of all outstanding shares of Loxo Oncology in a deal valued at approximately $8bn, boosting its oncology portfolio with precision medicines to potentially treat...

Go Top